CD Biosynsis offers state-of-the-art Mammalian Cells Base Editing Services, providing precise, single-nucleotide substitution without generating a DNA double-strand break (DSB). This advanced technology is ideal for highly controlled engineering of mammalian hosts like CHO (Chinese Hamster Ovary) cells and HEK293 cells. Base Editing (BE) is essential for applications requiring subtle genetic tuning, such as optimizing promoter strengths, tuning the expression of metabolic enzymes (e.g., LDHA), or introducing specific point mutations (SNPs) for disease modeling. By employing a fused dCas9 or nickase Cas9 (nCas9) with a specific deaminase, Base Editing converts one target base pair to another (e.g., C:G to T:A or A:T to G:C) with unparalleled efficiency and minimal byproducts. This platform is key to achieving precise, tunable control over complex cellular functions, leading to optimized specific productivity (Qp) and enhanced product quality for biotherapeutics.
Get a QuoteTraditional CRISPR-Cas9 often relies on the error-prone NHEJ pathway for knockouts or the low-efficiency HDR pathway for point mutations. Base Editing overcomes these limitations by performing the nucleotide conversion directly. This involves a complex fusion protein—typically a dCas9 or nCas9 (which nicks only one strand) linked to a cytidine deaminase (CBE) or an adenosine deaminase (ABE). The deaminase chemically converts the target base within the editing window specified by the gRNA. This DSB-free mechanism ensures high efficiency, low off-target effects, and minimal indel formation, making it the premier choice for subtle, tunable genomic control in mammalian production hosts and research models.
Cytidine Base Editors (CBE)
Fuses nCas9/dCas9 with a cytidine deaminase, facilitating the conversion of C:G base pairs to T:A base pairs (C>T conversion) within a defined editing window.
Adenosine Base Editors (ABE)
Fuses nCas9/dCas9 with an adenosine deaminase, enabling the conversion of A:T base pairs to G:C base pairs (A>G conversion), expanding the base editing scope.
Optimized Delivery Systems
Use of specialized, high-fidelity Base Editor variants (e.g., different Cas9 domains or optimized deaminases) delivered via plasmid or RNP to maximize on-target purity and minimize off-target edits.
Gene Expression Tuning
Introduction of precise point mutations into promoter, enhancer, or UTR sequences to subtly adjust gene expression levels, essential for controlling metabolic enzymes or host factors.
Stop Codon Insertion/Correction
Targeting specific codons to introduce premature stop codons for effective gene disruption (similar to KO but cleaner), or correcting premature stop codons in disease models.
Amino Acid Substitution
Creating specific missense mutations to modify protein function (e.g., enzyme kinetics) or introducing single-nucleotide polymorphisms (SNPs) for functional genomic studies.
Metabolic Pathway Balancing
Tuning the activity or expression level of enzymes like LDHA or PKM to safely shift glucose metabolism, reducing toxic lactate byproduct accumulation in CHO cells.
PTM Control and Quality
Editing cis-regulatory elements to modulate the expression of glycosylation enzymes or chaperone proteins, optimizing the specific product quality of therapeutic proteins.
Isogenic Disease Modeling
Precise introduction or correction of disease-associated SNPs into patient-derived or control cell lines for creating highly controlled isogenic pairs for drug discovery and validation.
A precision-guided process for single-nucleotide substitution and clonal verification.
1. Target Design & Editor Selection
2. Editor Delivery & Editing
3. Single Cell Cloning & Screening
4. Verification & Stable Clone Delivery
Identify the target base pair and the desired substitution (e.g., C>T or A>G). Select the optimal Base Editor (CBE or ABE) variant.
Design gRNA(s) to place the target base within the optimal editing window for high conversion efficiency and minimize off-target risk.
Define screening assays (e.g., sequencing, functional assay) to detect the desired point mutation.
Deliver the Base Editor (plasmid or RNP) and the optimized gRNA into the mammalian host line (Build) via electroporation or lipofection.
Culture cells for transient expression to allow the deaminase to perform the base conversion.
Apply selection markers or FACS sorting to enrich for high-editing populations.
Genotype verification via Sanger or Deep Sequencing across the edited window to confirm the base change, purity, and low indel rate (Learn).
Phenotypic validation of the final clone for stable expression of the modified trait (e.g., increased Qp, altered enzyme activity).
Delivery of the verified Master Cell Bank (MCB) or research clone and comprehensive documentation.
DSB-Free Precision
Elimination of the DNA double-strand break (DSB) ensures minimal indel formation, low toxicity, and clean, highly efficient base conversion, critical for delicate edits.
Tunable Genomic Control
Ideal for subtly tuning promoter elements and enzyme coding sequences, enabling precise control over metabolic flux and host factor expression for optimization.
High Efficiency in Mammalian Cells
Base editing is significantly more efficient than HDR for single-point mutations in CHO and HEK293 cells, accelerating the screening and cloning process dramatically.
Isogenic Model Fidelity
Allows for the precise introduction or correction of single nucleotide polymorphisms (SNPs) in patient-derived cell lines, creating high-fidelity, isogenic research models.
1. What types of base pair conversions can Base Editing achieve?
Currently, the most efficient and reliable Base Editors are Cytidine Base Editors (CBEs), which achieve C:G to T:A conversion, and Adenosine Base Editors (ABEs), which achieve A:T to G:C conversion.
2. Why is Base Editing better than traditional CRISPR/HDR for point mutations?
Base Editing avoids creating a double-strand break (DSB), minimizing the risk of unwanted indels. It also does not require the cell to enter the S or G2 phase for repair, leading to much higher editing efficiency than the HDR pathway in non-dividing or slow-dividing cells.
3. How is Base Editing used to optimize metabolic pathways in CHO cells?
It is used to subtly tune gene expression (e.g., weakening a promoter by a few percent) or introduce specific amino acid changes into metabolic enzymes (e.g., LDHA) to safely redirect carbon flux and reduce toxic byproduct formation without causing cell death.
4. What is the "editing window" for a Base Editor?
The editing window is the specific range of bases (typically positions 3-7 or 4-8) within the gRNA target sequence where the deaminase can successfully convert the target base. gRNA design must place the desired base within this window.
5. How is the final base change verified at the genomic level?
Verification is primarily performed via Sanger sequencing or Deep Sequencing of the PCR amplicon spanning the target region. This confirms the desired base conversion and quantifies the purity of the clone (percentage of cells edited) and the indel rate.
6. What input is required to start a Base Editing project?
We require the specific mammalian host cell line (e.g., CHO, HEK293) and the accession number or sequence of the target region, specifying the exact base pair change you wish to introduce.
7. Can Base Editing be used to mimic diseases in cell models?
Yes. Many human genetic diseases are caused by single nucleotide polymorphisms (SNPs). Base Editing is the ideal tool for precisely inserting these disease-associated SNPs into a control cell line, creating a robust isogenic disease model.
8. What is the biggest advantage of Base Editing for bioproduction hosts?
The biggest advantage is the ability to achieve subtle, non-lethal tuning of gene expression or enzyme function, allowing engineers to balance complex pathways (like metabolism or glycosylation) for peak performance without causing cell toxicity or genomic instability.
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.